Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials

Eric S Surrey, Ahmed M Soliman, Hannah L Palac, Sanjay K Agarwal, Eric S Surrey, Ahmed M Soliman, Hannah L Palac, Sanjay K Agarwal

Abstract

Background: Endometriosis profoundly impairs women's workplace and household productivity.

Objective: The aim of this study was to evaluate the impact of elagolix on endometriosis-related workplace and household productivity losses.

Methods: Data were pooled from two phase III trials of women aged 18-49 years with moderate to severe endometriosis-associated pain treated for 6 months with elagolix 150 mg daily (QD), 200 mg twice daily (BID), or placebo. The Health-Related Productivity Questionnaire was administered at baseline, Month 3, and Month 6 to determine workplace and household absenteeism and presenteeism. Productivity changes from baseline were compared between placebo and elagolix doses via analysis of covariance.

Results: Workplace analyses included 1270 employed women and household analyses included 1565 women. At baseline, women reported average weekly losses of 16 workplace hours, 8.3 household work hours, 45% of scheduled work, and 64% of planned household chores. At Month 6, treatment with elagolix 150 mg QD or 200 mg BID increased productive workplace hours by 1.7 (95% CI 0.1-3.4; p = 0.041) and 5.4 h (95% CI 3.7-7.1; p < 0.001) relative to placebo, corresponding to gains of 5.2% (95% CI 0.7-9.7; p = 0.022) and 14.6% (95% CI 10.0-19.1; p < 0.001) of scheduled work, respectively. Both elagolix doses improved household productivity at Month 6 by 1.7 (95% CI 0.7-2.7) and 3.1 (95% CI 2.1-4.0) hours relative to placebo (both p < 0.001), with increases of 8.8% (95% CI 3.5-14.1; p = 0.001) and 20.4% (95% CI 15.1-25.6; p < 0.001) of planned household work.

Conclusions: Treatment with elagolix improved endometriosis-related workplace and household productivity impairments.

Trial registration: ELARIS EM-I (NCT01620528) and ELARIS EM-II (NCT01931670).

Conflict of interest statement

Eric S. Surrey is Medical Director at Colorado Center for Reproductive Medicine, has served in a consulting role for AbbVie and DOT Laboratories, received research grants from AbbVie, and served on the speaker bureau for AbbVie and Ferring Laboratories. Ahmed M. Soliman is an employee of, owns stock/stock options, and holds patents for AbbVie. Hannah L. Palac was an employee of AbbVie Inc. at the time the research was conducted. Sanjay K. Agarwal is Director of Fertility Services in the UC San Diego Department of Reproductive Medicine, Director of the UC San Diego Center for Endometriosis Research and Treatment, and has served in a consulting role on research for AbbVie Inc. and has received research support from AbbVie Inc.

Figures

Fig. 1
Fig. 1
Gains in productive workplace hours per week at Months 3 and 6 of treatment. Mean hours gained in workplace productivity from baseline, defined as − 1 × LS mean change from baseline in hours of workplace productivity lost due to absenteeism, presenteeism, and total hours lost (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily
Fig. 2
Fig. 2
Gains in percentage of scheduled workplace productivity per week at Months 3 and 6 of treatment. Mean gains in the percentage of scheduled workplace hours worked, defined as − 1 × LS mean change from baseline in percentage of scheduled workplace hours lost due to absenteeism, presenteeism, and total (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily
Fig. 3
Fig. 3
Gains in hours of household productivity per week at Months 3 and 6 of treatment. Mean hours gained in household productivity, defined as − 1 × LS mean change from baseline in hours of household productivity lost due to absenteeism, presenteeism, and total (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily
Fig. 4
Fig. 4
Gains in percentage of planned household productivity per week at Months 3 and 6 of treatment. Mean gains in the percentage of planned household work hours worked, defined as − 1 × LS mean change from baseline in percentage of planned household work hours lost due to absenteeism, presenteeism, and total (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily

References

    1. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;19(4):406–418. doi: 10.1093/humupd/dmt010.
    1. Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Invest. 2017;82(5):453–461. doi: 10.1159/000452660.
    1. Abbas S, Ihle P, Koster I, Schubert I. Prevalence and incidence of diagnosed endometriosis and risk of endometriosis in patients with endometriosis-related symptoms: findings from a statutory health insurance-based cohort in Germany. Eur J Obstet Gynecol Reprod Biol. 2012;160(1):79–83. doi: 10.1016/j.ejogrb.2011.09.041.
    1. Wheeler JM. Epidemiology of endometriosis-associated infertility. J Reprod Med. 1989;34(1):41–46.
    1. Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–2704. doi: 10.1093/humrep/dei135.
    1. Johnson Neil P., Hummelshoj Lone, Abrao M.S., Adamson G.D., Allaire C., Amelung V., Andersson E., Becker C., Birna Árdal K.B., Bush D., de Bie B., Chwalisz K., Critchley H., D'Hooghe T., Dunselman G., Evers J.L.H., Farquhar C., Faustmann T., Forman A., Fourquet J., Fraser I., Giudice L., Gordts S., Guidone H., Guo S.W., Healy D., Hedon B., Hulkkonen J., Hull L., Hummelshoj L., Johnson N.P., Just M., Kiesel L., Lam A., Lynam C., Mettler L., Miller C., North H., Pai R., Petta C., Prentice L., Reilly S., Reis F., Rolla E., Rombauts L., Schweppe K.W., Seckin T., Sharpe-Timms K., Shepperson Mills D., Singh S., Soriano D., Stafford-Bell M., Stratton P., Taylor R., Tsaltas J., Veit J., Vercellini P. Consensus on current management of endometriosis. Human Reproduction. 2013;28(6):1552–1568. doi: 10.1093/humrep/det050.
    1. De Graaff A.A., D'Hooghe T.M., Dunselman G.A.J., Dirksen C.D., Hummelshoj L., Simoens S., Bokor A., Brandes I., Brodszky V., Canis M., Colombo G.L., DeLeire T., Falcone T., Graham B., Halis G., Horne A.W., Kanj O., Kjer J.J., Kristensen J., Lebovic D.I., Müller M., Vigano P., Wullschleger M. The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. Human Reproduction. 2013;28(10):2677–2685. doi: 10.1093/humrep/det284.
    1. Soliman AM, Coyne KS, Zaiser E, Castelli-Haley J, Fuldeore MJ. The burden of endometriosis symptoms on health-related quality of life in women in the United States: a cross-sectional study. J Psychosom Obstet Gynaecol. 2017;38(4):238–248. doi: 10.1080/0167482X.2017.1289512.
    1. Culley L, Law C, Hudson N, Denny E, Mitchell H, Baumgarten M, et al. The social and psychological impact of endometriosis on women’s lives: a critical narrative review. Hum Reprod Update. 2013;19(6):625–639. doi: 10.1093/humupd/dmt027.
    1. Nnoaham Kelechi E., Hummelshoj Lone, Webster Premila, d’Hooghe Thomas, de Cicco Nardone Fiorenzo, de Cicco Nardone Carlo, Jenkinson Crispin, Kennedy Stephen H., Zondervan Krina T. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertility and Sterility. 2011;96(2):366-373.e8. doi: 10.1016/j.fertnstert.2011.05.090.
    1. Fourquet J, Baez L, Figueroa M, Iriarte RI, Flores I. Quantification of the impact of endometriosis symptoms on health-related quality of life and work productivity. Fertil Steril. 2011;96(1):107–112. doi: 10.1016/j.fertnstert.2011.04.095.
    1. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27(5):1292–1299. doi: 10.1093/humrep/des073.
    1. Fourquet J, Gao X, Zavala D, Orengo JC, Abac S, Ruiz A, et al. Patients’ report on how endometriosis affects health, work, and daily life. Fertil Steril. 2010;93(7):2424–2428. doi: 10.1016/j.fertnstert.2009.09.017.
    1. Soliman AM, Coyne KS, Gries KS, Castelli-Haley J, Snabes MC, Surrey ES. The effect of endometriosis symptoms on absenteeism and presenteeism in the workplace and at home. J Manag Care Spec Pharm. 2017;23(7):745–754. doi: 10.18553/jmcp.2017.23.7.745.
    1. Soliman AM, Surrey E, Bonafede M, Nelson JK, Castelli-Haley J. Real-world evaluation of direct and indirect economic burden among endometriosis patients in the United States. Adv Ther. 2018;35(3):408–423. doi: 10.1007/s12325-018-0667-3.
    1. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2):740–745. doi: 10.1016/0002-9378(92)91706-g.
    1. Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–1691. doi: 10.1210/jc.2016-3845.
    1. Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. doi: 10.1056/NEJMoa1700089.
    1. Tundia N., Hass S., Fuldeore M., Wang L.L., Cavanaugh T., Boone J., Heaton P. Validation and u.s. Population norms of health-related productivity questionnaire. Value in Health. 2015;18(3):A24. doi: 10.1016/j.jval.2015.03.148.
    1. Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35. doi: 10.1186/s12955-017-0611-2.
    1. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443–2454. doi: 10.1001/jama.290.18.2443.
    1. Surrey ES, Soliman AM, Johnson SJ, Davis M, Castelli-Haley J, Snabes MC. Risk of developing comorbidities among women with endometriosis: a retrospective matched cohort study. J Womens Health (Larchmt). 2018;27(9):1114–1123. doi: 10.1089/jwh.2017.6432.
    1. Touboul C, Amate P, Ballester M, Bazot M, Fauconnier A, Darai E. Quality of life assessment using EuroQOL EQ-5D questionnaire in patients with deep infiltrating endometriosis: the relation with symptoms and locations. Int J Chronic Dis. 2013;2013:452134. doi: 10.1155/2013/452134.
    1. Surrey ES, Soliman AM, Agarwal SK, Snabes MC, Diamond MP. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertil Steril. 2019 doi: 10.1016/j.fertnstert.2019.02.031.
    1. Moradi M, Parker M, Sneddon A, Lopez V, Ellwood D. Impact of endometriosis on women’s lives: a qualitative study. BMC Womens Health. 2014;14:123. doi: 10.1186/1472-6874-14-123.
    1. Whelan E. ‘No one agrees except for those of us who have it’: endometriosis patients as an epistemological community. Sociol Health Illn. 2007;29(7):957–982. doi: 10.1111/j.1467-9566.2007.01024.x.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever